

NITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent No. 6,936,262)	Serial No. 10/055,174
Inventor(s): BRIGGS and TATUM)	Filed: January 25, 2002
Issue Date: August 30, 2005)	Attorney Docket No. 000295.00014

For: LKTA DELETION MUTANT OF P. HAEMOLYTICA

REQUEST FOR CERTIFICATE OF CORRECTION

U.S. Patent and Trademark Office Customer Service Window Randolph Building, Mail Stop: Certificate of Correction Branch 401 Dulany Street Alexandria, VA 22314

Certificate

MAR 2 1 2006

of Correction

Sir:

Please issue a Certificate of Correction in the above-identified patent. Two (2) copies of PTO Form 1050 are appended. The complete Certificate of Correction involves one page.

Relevant portions of (1) the Examiner's Amendment sent with the Supplemental Notice of Allowance dated January 24, 2005 and the (2) initialed Information Disclosure Statement returned with the Office Action dated May 12, 2003. These documents indicate that the errors in the issued patent were not the patentees' fault. Thus we believe no fee is due. If this is incorrect, please charge our Deposit Account No. 19-0733.

Respectfully submitted,

BANNER & WITCOFF, LTD.

Dated: March 17, 2006

1001 G Street, N.W. (11th Fl.) Washington, D.C. 20001

(202) 824-3000

Lisa M. Hemmendinger Registration No. 42,653

27 2000 TAR 21 2000

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO.:

6,936,262

DATED:

August 30, 2005

INVENTOR(S):

BRIGGS and TATUM

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the cover page, References Cited section (56), Other Publications: In the twelfth reference, please replace "al R," with --alcR--.

In Column 23, Claim 10, Line 67:
Please replace "an" with --and--.

Mailing Address of Sender:

Banner & Witcoff, Ltd. 11th Floor 1001 G Street, N.W. Washington, DC 20001-4597

FORM PTO 1050 (Rev.2-93)

U.S. PAT. NO 6,936,262

No. of add'l copies @ \$0.50 per page





2.4

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO.:

6,936,262

DATED:

August 30, 2005

INVENTOR(S):

BRIGGS and TATUM

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the cover page, References Cited section (56), Other Publications: In the twelfth reference, please replace "al R," with --alcR--.

In Column 23, Claim 10, Line 67:
Please replace "an" with --and--.


Mailing Address of Sender:

Banner & Witcoff, Ltd.
11th Floor
1001 G Street, N.W.
Washington, DC 20001-4597

FORM PTO 1050 (Rev.2-93)


U.S. PAT. NO 6,936,262

No. of add'l copies @ \$0.50 per page



U





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/055,174 01/25/2002		Robert E. Briggs	000295.00014	9144	
22907 7	7590 01/24/2005		EXAM	INER	
BANNER & 1001 G STREI			GRASER, JE	ENNIFER E	
SUITE 1100			ART UNIT	PAPER NUMBER	
WASHINGTON, DC 20001		1645			
	<u>-</u>	DATE MAILED: 01/24/2005			

Please find below and/or attached an Office communication concerning this application or proceeding.

000295.00014

JAN 2 7 2005 BG

BANNER & WITCOFF, LTD ECVD

	OFFE	
Notice of Allowability Exar	MAR 1 7 2006 BR	oplicant(s) RIGGS ET AL. t Unit
The MAILING DATE of this communication appears of All claims being allowable, PROSECUTION ON THE MERITS IS (OR R herewith (or previously mailed), a Notice of Allowance (PTOL-85) or oth NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS of the Office or upon petition by the applicant. See 37 CFR 1.313 and N	the cover sheet with the correse EMAINS) CLOSED in this application will be application with this application is subject to with	spondence address tion. If not included be mailed in due course. THIS
1. This communication is responsive to		
2. The allowed claim(s) is/are <u>36-41,66,81-88,91,92 and 95-101</u> .		
3. The drawings filed on 25 January 2002 are accepted by the Exam	niner.	
4. Acknowledgment is made of a claim for foreign priority under 35 a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been 2. Certified copies of the priority documents have been	received.	
3. Copies of the certified copies of the priority document	s have been received in this natior	nal stage application from the
International Bureau (PCT Rule 17.2(a)). * Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this conted below. Failure to timely comply will result in ABANDONMENT of THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be submitted. NINFORMAL PATENT APPLICATION (PTO-152) which gives reason.	this application. ote the attached EXAMINER'S AM	MENDMENT or NOTICE OF
6. CORRECTED DRAWINGS (as "replacement sheets") must be su		
(a) ☐ including changes required by the Notice of Draftsperson's Pa		attached
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amen Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) seach sheet. Replacement sheet(s) should be labeled as such in the head	er according to 37 CFR 1.121(d).	the front (not the back) of
7. DEPOSIT OF and/or INFORMATION about the deposit of B attached Examiner's comment regarding REQUIREMENT FOR THE	IOLOGICAL MATERIAL must b IE DEPOSIT OF BIOLOGICAL MA	be submitted. Note the ATERIAL,
Attachment(s) 1. Notice of References Cited (PTO-892)	5. Notice of Informal Patent	Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary (PTO-	
 3. Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit 	Paper No./Mail Date	<u>Comment</u>
of Biological Material	9. Other Jeni Prin	Inifer E. Graser 2/05 Unit: 1645

U.S. Patent and Trademark Office PTOL-37 (Rev. 1-04)

Notice of Allowability

Part of Paper No./Mail Date 20050112

27 2060

Application/Control Number: 10/055,174

Art Unit: 1645

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Lisa Hemmindinger on January 10, 2004. This Supplemental amendment is merely to correct typographical errors found in the Examiner's Amendment mailed on 12/21/04.

Claims 36-41, 66, 81-88, 91, 92, and 95-101 are allowed.

The application has been amended as follows:

Please substitute/amend claims 81, 91 and 95 with the following claims:

- ruminants, comprising administering a vaccine formulation which comprises:
- (a) a killed *P.haemolytica* bacterium which contains no non-*P.haemolytica* DNA and which expressed a deletion mutant leukotoxin when it was alive; and
- (b) a *P.haemolytica* deletion mutant leukotoxin in the form of a purified protein or in a preparation selected from the group consisting of a bacterial lysate, a bacterial extract, and a culture supernatant;

wherein the deletion leukotoxin molecules of (a) and (b) have a molecular weight of about 66 kDa, lack amino acid residues 34 to 378 of the wild-type leukotoxin molecule,

Application/Control Number: 10/055,174

Art Unit: 1645

and induce antibodies which specifically bind to and neutralize biologically active leukotoxin.

- 91. (presently amended) A feed for ruminants which comprises:
- (a) a killed *P.haemolytica* bacterium which contains no non-*P.haemolytica* DNA and which expressed a deletion mutant leukotoxin when it was alive; and
- (b) a *P.haemolytica* deletion mutant leukotoxin in the form of a purified protein or in a preparation selected from the group consisting of a bacterial lysate, a bacterial extract, and a culture supernatant;


wherein the deletion leukotoxin molecules of (a) and (b) have a molecular weight of about 66 kDa, lack amino acid residues 34 to 378 of the wild-type leukotoxin molecule, and induce antibodies which specifically bind to and neutralize biologically active leukotoxin.

- 95. (presently amended) A vaccine for reducing morbidity in ruminants, comprising:
- (a) a killed P.haemolytica bacterium which contains no non-P.haemolytica DNA and

which expressed a deletion mutant leukotoxin when it was alive; and

(b) a *P.haemolytica* deletion mutant leukotoxin in the form of a purified protein or in a preparation selected from the group consisting of a bacterial lysate, a bacterial extract, and a culture supernatant;

wherein the deletion leukotoxin molecules of (a) and (b) have a molecular weight of about 66 kDa, lack amino acid residues 34 to 378 of the wild-type leukotoxin molecule,



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Virginia 22313-1450

APPLICATION NO.	FILING	DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/055,174	01/25 7590	/2002 05/12/2003	RECEIVED	000295.00014	9144	
BANNER & WITCOFF		Ittil a mana	EXAMINER			
1001 G STREET N W SUITE 1100	1047 1 5 7003	GRASER, JENNIFER E				
WASHINGT	ON, DC 200	001	BANNER WITCOFF	ART UNIT	PAPER NUMBER	
·				1645 DATE MAILED: 05/112/2003	6	

Please find below and/or attached an Office communication concerning this application or proceeding.

DOCKETEDSH

MAY 1 5 2003

Amend duc: 8.12.0

Last day: 11.12.0:

Office Action

Application No. 10/055,174 Applicant(s)

Btiggs et al.

Examiner

Art Unit



Jennifer Graser 1645 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**Period for Reply** A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). **Status** 1) Responsive to communication(s) filed on *Election*, 4/21/03 2a) \square This action is **FINAL**. 2b) This action is non-final. 3) \square Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. Disposition of Claims 4) X Claim(s) 36-41 and 66-95 _____ is/are pending in the application. 4a) Of the above, claim(s) ______ is/are withdrawn from consideratio 5) ☐ Claim(s) _ is/are allowed. 6) 💢 Claim(s) <u>36-41 and 66-95</u> is/are rejected. 7) Claim(s) _____ is/are objected to. 8) Claims are subject to restriction and/or election requirement **Application Papers** 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on ______ is/are objected to by the Examiner. 11) The proposed drawing correction filed on approved by disapproved. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). a) \square All b) \square Some* c) \square None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). Attachment(s) 15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s). 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152) DUUL F (17) M. Information Disclosure Statement(s) (PTO-1449) Paper No(s). 4 20) ... Other:

CH CHARLES TO SERVICE		OIPE	40	BEST	AVAILAE	BLE CO			
U.S.	PTO-1449 (Modified) MAR 1 7 2006 U.S. DEPARTMENT OR COMMERCE			ATTY. DOCKET NO. SEPTAL NUMBER D 09/245,331		Sheet of Div. of			
PATE	ENT AND TRADEM	K OFFICE	A	PPLICANT Briggs a	nd Tatúm				
INFORM	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FI .	FILING DATE Herewith		GROUP 1.64	GROUP ART UNIT (Prior)		
			U.S. PA	TENT DOCUM	ENTS				
EXAMINER INITIAL	DOCUMENT NUMBER	DATE		МАМ		CLASS	SUB CLASS	FILING DATE	
					•				
					·				
	·	FOR	EIGN P	ATENT DOCUM	MENTS				
EXAMINER INITIAL	DOCUMENT NUMBER	DATE		COUNT	RY	CLASS	SUB CLASS	Translation YES/NO	
	OTHER D	OCUMENTS (1	ncluding	Author, Title, l	Date, Pertinent Pa	ages, Etc.)			
1	Homchampa et al. "C Vaccine 1997 Vol. 1:	ross protective i					eurella mult	ocida"	
	Beaumont et al. "Ider Siderophore Biosynth Bacteriology, Februa	Acre with Tidlizin	un in Ko	MIPIPIIA BBANKURNI	c and Danisail - 1	AraC-Like R ronchiseptica*	egulator of A Journal of	Alcaligin	
	Link et al. "Methods Application to Open I 179, No. 20	for Generating P	recise D	eltions and Insert	ions in the Garage	e of Wild-Typ ctober 1997, p	e Escherichi gs. 628-623	la coli: 7, Vol.	
	Cotter and Miller "By bronchiseptica in a Re	gAS-Mediated Sabbit Model" Inf	ignal Tra	ansduction: Analy	ysis of Phase-Lock ust 1994, pgs. 338	ed Regulatory	Mutants of	Bordetella	
<u> </u>	Hamilton et al. "New Bacteriology, Septemi	Method for Gen	costing I	Peletions and Good	a Dantasaasaa t			of	
EXAMINER	04	102/	1	DATE CONS	SIDERED S	8/0			
EXAMINER: Li considered. Inc	nitial citation it reference	e was considered with next commi	I. Draw	line through citat	tion if not in confo	ormance to MI	PEP 609 and	not	